LV Global Longitudinal Strain (LV GLS) offers superior sensitivity in evaluating early left ventricular dysfunction, even when traditional measures like ejection fraction appear normal. Unlike basic 2D echocardiography, which relies on visual estimations, strain imaging uses speckle-tracking technology to measure how well the myocardial fibers shorten and stretch along the heart’s long axis. This makes it exceptionally valuable in identifying subclinical heart disease—especially in patients undergoing chemotherapy, those with hypertension, diabetes, valvular heart disease, or suspected cardiomyopathy.

LV GLS plays a crucial role in monitoring cardiotoxicity in cancer patients, guiding early intervention before permanent cardiac damage occurs. It also improves diagnostic precision in heart failure with preserved ejection fraction (HFpEF), where patients may show symptoms despite having a normal EF. Because of its reproducibility and predictive power, LV GLS is now being integrated into routine heart failure assessment, cardio-oncology protocols, and long-term cardiovascular monitoring plans, helping clinicians make more accurate and timely decisions for patient care.